A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination

作者：Filippatos Theodosios D^*

来源：Cardiovascular Drugs and Therapy, 2012, 26(3): 245-255.

DOI：10.1007/s10557-012-6394-0

• Fenofibric acid
• Fibrate
• Statin
• Simvastatin
• Atorvastatin
• Rosuvastatin
• Triglycerides
• High-density lipoprotein cholesterol

Fibrates activate peroxisome proliferator activated receptor alpha and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.

• 出版日期2012-6